Fiche du document
8 avril 2022
- doi: 10.1093/nar/gkac161
- issn: 0305-1048
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/nar/gkac161
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35286377
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1362-4962
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E80CB0AB76D90
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Phosphonucleosides Pattern Model Resultants AminopurineCiter ce document
A. Pallaseni et al., « Predicting base editing outcomes using position-specific sequence determinants. », Serveur académique Lausannois, ID : 10.1093/nar/gkac161
Métriques
Partage / Export
Résumé
CRISPR/Cas base editors promise nucleotide-level control over DNA sequences, but the determinants of their activity remain incompletely understood. We measured base editing frequencies in two human cell lines for two cytosine and two adenine base editors at ∼14 000 target sequences and find that base editing activity is sequence-biased, with largest effects from nucleotides flanking the target base. Whether a base is edited depends strongly on the combination of its position in the target and the preceding base, acting to widen or narrow the effective editing window. The impact of features on editing rate depends on the position, with sequence bias efficacy mainly influencing bases away from the center of the window. We use these observations to train a machine learning model to predict editing activity per position, with accuracy ranging from 0.49 to 0.72 between editors, and with better generalization across datasets than existing tools. We demonstrate the usefulness of our model by predicting the efficacy of disease mutation correcting guides, and find that most of them suffer from more unwanted editing than pure outcomes. This work unravels the position-specificity of base editing biases and allows more efficient planning of editing campaigns in experimental and therapeutic contexts.